Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Clinical Trial ID NCT00064129

Rank	Title	Journal	Year	PubWeight™‹?›
1	Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.	Sci Transl Med	2014	2.50
2	At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.	J Leukoc Biol	2013	1.90
3	CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.	Blood	2008	1.81
4	The changing therapeutic landscape of castration-resistant prostate cancer.	Nat Rev Clin Oncol	2011	1.55
5	Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.	J Immunol	2012	1.09
6	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
7	Unmasking the immune recognition of prostate cancer with CTLA4 blockade.	Nat Rev Cancer	2012	0.89
8	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.	Int J Mol Sci	2013	0.88
9	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.	Vaccines (Basel)	2016	0.82
10	Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?	Cancer Med	2013	0.75
11	Immunotherapy in genitourinary malignancies.	Curr Opin Urol	2016	0.75
12	A Perspective of Immunotherapy for Prostate Cancer.	Cancers (Basel)	2016	0.75